Optic nerve thinning and neurosensory retinal degeneration in the rTg4510 mouse model of frontotemporal dementia by Harrison, IF et al.
RESEARCH Open Access
Optic nerve thinning and neurosensory
retinal degeneration in the rTg4510 mouse
model of frontotemporal dementia
Ian F. Harrison1* , Rozalind Whitaker2, Pietro Maria Bertelli2,4, James M. O’Callaghan1, Lajos Csincsik2,4,
Martina Bocchetta3, Da Ma1,5, Alice Fisher6, Zeshan Ahmed6, Tracey K. Murray6, Michael J. O’Neill6,
Jonathan D. Rohrer3, Mark F. Lythgoe1 and Imre Lengyel2,4
Abstract
Visual impairments, such as difficulties in reading and finding objects, perceiving depth and structure from motion,
and impaired stereopsis, have been reported in tauopathy disorders, such as frontotemporal dementia (FTD). These
impairments however have been previously attributed to cortical pathologies rather than changes in the neurosensory
retina or the optic nerve. Here, we examined tau pathology in the neurosensory retina of the rTg(tauP301L)4510
mouse model of FTD. Optic nerve pathology in mice was also assessed using MRI, and corresponding measurements
taken in a cohort of five FTD sufferers and five healthy controls. rTg(tauP301L)4510 mice were imaged (T2-weighted
MRI) prior to being terminally anesthetized and eyes and brains removed for immunohistochemical and histological
analysis. Central and peripheral retinal labelling of tau and phosphorylated tau (pTau) was quantified and retinal layer
thicknesses and cell numbers assessed. MR volumetric changes of specific brain regions and the optic nerve were
compared to tau accumulation and cell loss in the visual pathway. In addition, the optic nerves of a cohort of healthy
controls and behavioural variant FTD patients, were segmented from T1- and T2-weighted images for volumetric study.
Accumulation of tau and pTau were observed in both the central and peripheral retinal ganglion cell (RGC), inner
plexiform and inner nuclear layers of the neurosensory retina of rTg(tauP301L)4510 mice. This pathology was
associated with reduced nuclear density (− 24.9 ± 3.4%) of the central RGC layer, and a reduced volume (− 19.3 ± 4.6%)
and elevated T2 signal (+ 27.1 ± 1.8%) in the optic nerve of the transgenic mice. Significant atrophy of the cortex
(containing the visual cortex) was observed but not in other area associated with visual processing, e.g. the lateral
geniculate nucleus or superior colliculus. Atrophic changes in optic nerve volume were similarly observed in FTD
patients (− 36.6 ± 2.6%). The association between tau-induced changes in the neurosensory retina and reduced optic
nerve volume in mice, combined with the observation of optic nerve atrophy in clinical FTD suggests that ophthalmic
tau pathology may also exist in the eyes of FTD patients. If tau pathology and neurodegeneration in the retina were to
reflect the degree of cortical tau burden, then cost-effective and non-invasive imaging of the neurosensory retina
could provide valuable biomarkers in tauopathy. Further work should aim to validate whether these observations are
fully translatable to a clinical scenario, which would recommend follow-up retinal and optic nerve examination in FTD.
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Introduction
Frontotemporal dementia (FTD) is a neurodegenerative
disorder characterised by degeneration within the frontal
and temporal lobes of the brain [20, 41, 46]. The disorder
presents clinically with changes in behaviour, deficits in
executive function and/or language impairment, but in
some cases can also manifest with a motor disorder such
as corticobasal syndrome, motor neuron disease or pro-
gressive supranuclear palsy (PSP) [44]. Around 30–50% of
FTD cases are familial in nature, with an autosomal dom-
inant profile of inheritance [44], and in a subset of these
cases, causative mutations in the microtubule associated
protein tau (MAPT) gene have been identified [16]. Such
mutations lead to disruption of the normal binding of tau
to neuronal tubulin, resulting in pathological deposition of
hyperphosphorylated tau in the form of filamentous neur-
onal inclusions, or neurofibrillary tangles (NFTs) [16, 39].
NFTs are also observed in other pathologies such as Alz-
heimer’s disease (AD), Pick’s disease, corticobasal degener-
ation and PSP, a group of neurological disorders
collectively known as tauopathies.
Numerous reports exist of early stage tauopathy patients
experiencing cognitive visual changes, including changes
in colour recognition [9], impairment of spatial contrast
sensitivity [15], depth perception [28], perceiving structure
from motion [10, 28], and also difficulties with reading
and finding objects [21]. Previously however, these defects
have been attributable to the well described cortical tau
pathology in the brains of patients with tauopathies rather
than the result of tau pathology in the optic nerve or neu-
rosensory retina. Responsible for converting incoming
light into encoded neural activity, the neurosensory retina
is a laminal structure of nuclear and neuropil plexiform
layers, formed by a tripartite neuronal relay: Photorecep-
tors - > Bipolar cells - > Retinal Ganglion Cells (RGCs),
which is modulated by two classes of interneurons, Hori-
zontal and Amacrine cells, and supported by Müller glia.
RGC axons converge in the Retinal Nerve Fibre Layer
(RNFL) to form the optic nerve, which then projects to
the visual centres of the brain for higher order processing
of input signals. With advancing age, tau becomes
expressed diffusely within the inner nuclear layer (INL),
and the retinal ganglion cell layer (RGCL) of the human
neurosensory retina [24]. Furthermore in ocular diseases
such as glaucoma, abnormally phosphorylated tau is
increased in the INL and inner plexiform layer (IPL) of
the retina [17, 31, 48], an observation which has similarly
been made in a mouse model of ocular hypertension in-
duced glaucoma [8]. Based on this evidence, that tau path-
ology also affects the eye, we hypothesized that retinal and
optic nerve changes might also be associated with the
pathologies in tauopathic dementias such as FTD.
Assessments of retinal changes in mice expressing the
P301S mutated human MAPT gene driven by the mouse
Thy1.2 promoter (mThy1.2) showed increased phos-
phorylation of tau in the RGCL and filamentous inclu-
sions in the retina [14] without an effect on RGC
number. In transgenic mice expressing the P301L muta-
tion in the human MAPT gene however, driven by the
mouse prion promoter (PRNP), total tau and phosphory-
lated tau levels were shown to be elevated in the RGCL,
the IPL and also the INL, accompanied by a reduction
in the thickness of the INL, an effect which was more
pronounced in the peripheral compared to the central ret-
ina [18]. These changes were accompanied by an increase
in the number but reduction in the average size of RGCs
in the transgenic mice [18]. Together these data highlight
the susceptibility of the neurosensory retina to mutations
associated with familial FTD, and hence highlights the
possibility of retinal changes in the clinical scenario. How-
ever both of these transgenic models (MAPT P301S
driven by mThy1.2 [14], and MAPT P301L driven by
PRNP [18]) show ubiquitous expression of pathological
phosphorylated tau throughout the brain, quite unlike the
pathological spatial pattern of tau observed in FTD [20,
41, 46]. Therefore, in order to better understand the
effects of mutations associated with familial FTD on the
neurosensory retina and visual system, we studied an ani-
mal model that shows spatial patterns of tau deposition
similar to that seen in clinical FTD.
In the current study we assessed retinal tau pathology in
the rTg(tauP301L)4510 mouse model, which harbours the
same P301L mutant form of the human MAPT gene pre-
viously described in the study by Ho et al. [19], but driven
by the forebrain-specific calmodulin kinase II a (CaMKIIa)
promoter system, which results in NFT pathology in fore-
brain structures and the hippocampus, reminiscent of the
pattern for tau accumulation observed in FTD [20, 41,
46]. Using this animal model, we show increased phos-
phorylated tau expression in the RGCL, as well as a de-
crease in RGC numbers in the neurosensory retina
associated with volumetric changes (assessed through
MRI) in the optic nerve and areas of the mouse brain in-
volved in visual processing. In addition, a cohort of FTD
patients carrying the MAPT mutation were imaged with
MRI, and we show that similar to mice, volumetric
changes in the optic nerve do take place in familial FTD.
Materials and methods
Animals
Generation of homozygous rTg(tauP301L)4510 trans-
genic mice, henceforth referred to as rTg4510 mice, has
been described previously [43]. The rTg4510 and litter
matched wildtype mice were bred on a mixed FVB/NCrl
+129S6/SvEvTa background for Eli Lilly by Taconic
(Germantown, Maryland, USA), licensed from the Mayo
Clinic (Jacksonville, Florida, USA), and imported into
the United Kingdom for study at the UCL Centre for
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Advanced Biomedical Imaging. Mice were kept in indi-
vidually ventilated cages in groups of 3–5, with ad libi-
tum access to food and water. Animal weight was
monitored upon arrival and until experimentation, and
all animals were deemed healthy prior to experiments.
For this study, import of 10 female 7.5 month of age
rTg4510 and 10 female litter matched wildtype mice oc-
curred two weeks prior to initial imaging studies and
subsequent sacrifice, perfuse fixation, and sectioning for
immunofluorescent analysis. All the experiments were
performed in accordance with the Animals (Scientific
Procedures) Act 1986 (ASPA) revised according to the
European Directive 2010/63/EU and the UK Home Of-
fice (Scientific Procedures) Act (1986) with prior project
approval from UCL’s internal Animal Welfare and Eth-
ical Review Body.
Magnetic resonance imaging of mice
Image acquisition
All imaging was performed with a 9.4 T VNMRS horizon-
tal bore scanner (Agilent Inc). A 72mm inner diameter
volume coil (Rapid Biomedical) was used for radiofre-
quency transmission, and signal was received using a
4-channel array head coil (Rapid Biomedical). Mice were
placed in an induction box before anaesthesia was induced
using 2% isoflurane at 1 L/min in 100% O2. Mice were
subsequently positioned in an MRI-compatible head
holder to minimize motion artefacts. Anaesthesia was
maintained throughout imaging using 1.5% (± 0.2%) iso-
flurane at 1 L/min in 100% O2 delivered via a nose cone,
which permitted spontaneous breathing of the mice. Core
temperature and respiratory rate were monitored using a
rectal probe and pressure pad, respectively (SA Instru-
ments). Mice were maintained at ∼37 °C using heated
water tubing and a warm air blower with a feedback sys-
tem (SA Instruments). Respiration rate was maintained
between 80 and 120 breaths per minute by manually
adjusting the isoflurane vaporizer.
A 3-dimensional T2-weighted fast spin echo sequence
was employed for structural imaging with the following
parameters: field of view (FOV) = 19.2 × 16.8 × 12.0mm,
resolution = 150 × 150 × 150 μm, repetition time (TR) =
2500ms, effective echo time = 43ms, echo train length =
4, number of signal averages = 1, and imaging time = 1.5 h.
Mice were imaged in a random order, working through
cages which housed a mixture of rTg4510 and litter
matched wildtype mice.
Image analysis
For manual segmentation of the optic nerve and eye
structures for extraction of volumes and signal inten-
sities on T2-weighted images, ITK-SNAP segmentation
software (v3.x) [49] was used. For extraction of brain
volumes, a multi-atlas-based structural parcellation
framework was used [25]. Using this framework, we ex-
tracted 4 structures of interest to the visual system and
dementia: the cortex (containing the visual cortex), thal-
amus (containing the lateral geniculate nucleus), hippo-
campus, and superior colliculus. The lateral geniculate
nucleus and superior colliculus were of interest as in both
humans and mice they are key targets of optic tract axons,
and contribute to visual processing, as well as acting as a
relay to other destinations in the visual pathway. In
addition, we extracted the volume of the whole brain for
normalisation purposes. For this, brain images were ori-
ented, non-uniformity corrected, and skull stripped. We
adopted the publicly available in vivo mouse brain MRI
atlas previously published for the framework [26]. First,
the atlas images were registered affinely to the original
MR image data using a block-matching algorithm [36].
Once complete, the STAPLE algorithm [25] was applied
to fuse the resampled atlas masks together to create a con-
sensus brain mask for each animal’s scans. A further
non-rigid registration based on fast free-form deformation
was then performed to correct any remaining local mis-
alignment of the affinely registered atlas to the brain vol-
umes [30]. The structural labels from the atlas were then
transformed and resampled to the image space of the
brain scans using the same affine and non-rigid trans-
formation and fused using the STEPS label fusion algo-
rithm [22] to create the final parcellated structures of
interest: the cortex, thalamus, hippocampus, and superior
colliculus. A previously published calibration protocol was
used to correct gradient scaling errors in the data [32].
Both absolute volumes and volumes normalised to the ex-
tracted whole brain volume are presented.
CSF extraction, perfuse fixation and tissue preparation for
histology
Following in vivo MR imaging, animals were terminally
anaesthetised with an overdose of Euthanal administered
via intraperitoneal injection. A midline incision was made
at a midpoint between the skull base and the occipital
margin to the first vertebrae. The underlying muscles were
parted to expose the atlanto-occipital membrane and dura
mater overlaying the cisterna magna. The area was
cleaned and a durotomy performed with a 23-gauge nee-
dle, allowing CSF to be collected using a narrow bore pip-
ette tip. The thoracic cavities were then opened and the
animals were intracardially perfused through the left ven-
tricle: first with 15–20mL of saline (0.9%) and heparin;
second with 50mL of Formalin, at a flow rate of 3 mL per
minute. Following perfusion, the animal was decapitated,
de-fleshed, and the head stored at 4 °C and soaked in For-
malin for 9 weeks. Brains were removed from the skull
and processed using the Tissue TEK VIP processor (GMI
Inc.) and embedded in paraffin wax. 6 μm thick sections
of the brain in the sagittal plane were collected using a
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rotary microtome and mounted on glass slides for immu-
nohistochemistry. The eye globes were enucleated, proc-
essed (Leica ASP3005) and embedded in paraffin in an
orientation that facilitated sectioning in transverse planes.
Ice cooled paraffin tissue blocks were sectioned (Leica
RM2235 Microtome using S35-PFM feather microtome
blades) to generate 4 μm sections which were then placed
in a 45 °C water bath. Once mounted onto Super-Frost
Plus slides, sections were drip-dried for 2–5 min before
heat fixing for 60 mins. Haematoxylin and Eosin (H&E)
staining (Autostainer Leica CV5030) and light microscopy
(Olympus multi-head light microscope with Micropixx
camera software) enabled semi-quantitative morphometric
analysis (Image J) and identification of each sections
anatomical location in the retinal peripheral-central axis.
Sections within 25 μm of the optic nerve head were subse-
quently used for immunohistochemical staining. The cen-
tral and peripheral retina were defined as the most lateral
and central non-fragmented region of each tissue section
(Additional file 1: Figure S1). H&E derived semi-quantita-
tive data included Retinal Ganglion Cell Layer (RGCL)
nuclear densities and Inner Nuclear Layer (INL) nuclear
densities (number of nuclei occupying a measured area of
RGCL or INL respectively), and Inner Plexiform Layer
(IPL) thickness relative to total retinal thickness. This data
was generated for peripheral and central retinal regions.
Quantification of CSF tau
The collected CSF was centrifuged briefly to collect any
red blood cell contaminates, the supernatant removed
and frozen at − 20 °C until further analysis by ELISA.
2 μl water was added to the blood pellet and snap frozen
on dry ice to ensure hypotonic freeze-thaw release of
haemoglobin from any red blood cells present. Each
sample was measured at 417 nm on a NanoDrop spec-
trophotometer to quantify percentage blood contamin-
ation of each CSF sample. This method allows for
measurement of blood contamination down to 0.0001%,
well below that detectable by eye (~ 0.01%). Lack of sig-
nificant blood contamination was verified by an average
percentage contamination of 0.003% (±0.0006%). Tau
content of CSF samples were quantified using both the
Human Tau (total), and Human pTau [pS199] ELISA Kits
(Invitrogen, UK) as per the manufacturer’s instructions.
Immunohistochemistry
For immunohistochemistry in the retina, retinal sections
from 5 rTg4510 and 4 wildtype mice were deparaffinised
and hydrated by sequential immersion in xylene, 3 suc-
cessive ethanol solutions (100, 90, and 70%) and distilled
water. As tau proteins largely have intracellular distribu-
tions, permeabilisation of nuclear and plasma mem-
branes was carried out using detergents: Tween-20
(0.05%: Sigma-Aldrich P1379) in citrate buffer (Citric
acid, anhydrous, Sigma-Aldrich C1857-100G), and
Triton-X-100 (0.1%: Sigma-Aldrich T8787-50ML) in
phosphate buffered saline (PBS: Gibco 20,012–019)
forming PBST. Antigen retrieval was achieved through
heating sections in a microwave (setting to 800W) in
citrate buffer (pH 6.0) for 5 mins before slides were left
to gradually cool to room temperature (RT) for 20 mins.
Following two 5min PBS washes, sections were blocked
with goat serum (Sigma-Aldrich, G9023-10M: 1:20 in
PBST) for 1 h at RT. After performing two 3min PBST
washes sections were incubated with primary anti-pTau
(Thermo Scientific MN1020, mouse monoclonal AT8:
1:100 dilution in PBST) and anti-Tau (Dako, rabbit poly-
clonal A0024: 1:2000 dilution in PBST) antibodies for 1
h at RT. A0024 binds to total tau independent of phos-
phorylation (amino acids 243–441) whereas AT8 binds
to aberrantly phosphorylated tau species (pS202/pT205).
Negative controls, where no primary antibody incuba-
tion was performed, were conducted alongside each ex-
perimental run (Additional file 1: Figure S2). Following
three washes with PBST (5 mins each) sections were in-
cubated with fluorophore conjugated complementary
secondary antibodies at RT for 1 h (Alexa-Fluor 568 goat
anti-mouse A21124 and Alexa-Fluor 647 goat anti-rabbit
A21244, Life Technologies: 1:200 dilution in PBST).
This, and all subsequent stages were conducted in the
dark to prevent photobleaching. Sections underwent
three further 5 min PBST washes, and were then incu-
bated with Hoechst stain (16.2 mM stock solution di-
luted to 1:5000 in PBS) for 15 mins at RT to provide
blue nuclear staining. Two 3min PBS washes followed.
Slides were coverslipped (Mansel-Gläser 24 × 60mm)
following the application of Vectashield anti-fade
mounting medium (Vector Laboratories, H-1000) and
stored at 4 °C until imaged. Fluorescent confocal micros-
copy (Zeiss LSM510 confocal microscope with Zen 2
software) generated qualitative and semi-quantitative
data. Constant standardised settings were used for com-
parative non-adjusted imaging, and optimised settings
used for adjusted imaging. This semi-quantitative data
included the number of pTau positive cells in the RGCL
and INL, and the mean intensity per pixel of areas of in-
dividual retinal strata (RGCL, IPL, INL and photorecep-
tor inner segment (PIS)). Data was generated by using
Zen & Image J softwares to analyse images of central
and peripheral retinal regions. This data, like the
semi-quantitative data acquired from H&E images,
allowed comparison between rTg4510 and wildtype ret-
inas, and between the central and peripheral retina.
For immunohistochemistry in the brain, brain sections
were deparaffinised and hydrated by sequential
immersion in xylene, 3 successive ethanol solutions
(100, 90, and 70%) and distilled water. Antigen retrieval
was performed using the Lab Vision PT module system
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(Thermo Scientific), where sections were heated to 100 °
C for 20 min in citrate buffer (TA-250-PM1X; Thermo
Scientific). Slides were transferred to a Lab Vision Auto-
stainer (Thermo Scientific) where the following incuba-
tions were performed: 10 min in H2O2 (0.3%); 30 min in
normal goat serum (1:20; Vector Laboratories); 60 min
in primary antibody for aberrantly phosphorylated
(pS409) tau (PG-5; 1:8000 from Peter Davies, Albert Ein-
stein College of Medicine, NY, USA); 30 min in biotinyl-
ated goat anti-mouse IgG (1:200, BA9200; Vector
Laboratories); 30 min avidin-biotin complex solution
(PK-7100; Vector Laboratories); 5 min in 3,3′-diamino-
benzidine (SK-4105; Vector Laboratories). Apart from
the last two steps, PBST was used for diluting reagents
and washes between steps. Sections were then counter-
stained with haematoxylin before dehydration and
cover-slipping. To quantify PG-5-positive tau pathology,
stained sections were digitised using the Scanscope AT
slide scanner (Aperio) at 20× magnification. Image J
software was used to view the digitised tissue sections,
threshold for immunoreactivity and delineate boundaries
of the visual cortex, hippocampus, thalamus, superior
colliculus and optic tract. Data is expressed as the per-
centage coverage of immunoreactivity in each region.
Magnetic resonance imaging of humans
Participants
Five male subjects fulfilling the criteria for the diagnosis of
behavioural variant FTD [40] and carriers of a mutation in
theMAPT gene (three 10 + 16 and two R406W mutations)
were consecutively recruited from a tertiary referral cogni-
tive disorders clinic at the National Hospital for Neur-
ology and Neurosurgery, London, UK. Five healthy
controls were also consecutively recruited (1 female, age
range: mean(standard deviation) 62(11) years). Patients’
age: 64(3) years; disease duration: 9(3) years; age at onset:
55(1) years. A full clinical history including ophthalmic
history was taken from all patients as part of the standard
assessment. Hence the patients (and controls) included in
this study were free of any retinal or eye disease which
may have confounded the data presented.
Image acquisition
Volumetric T1- and T2-weighted MRI was performed in
all subjects. MRI scans were acquired on a 3 T scanner
(Tim Trio, Siemens) with the following sequences: (i)
high-resolution isotropic 3D T1-weighted MPRAGE (sa-
gittal orientation; TR = 2200 ms, TI = 900 ms, TE = 2.9
ms, flip angle = 10°, acquisition matrix = 256 × 256 and
spatial resolution = 1.1 mm); and (ii) high-resolution iso-
tropic 3D T2-weighted fast spin echo/SPACE (sagittal
orientation; TR = 3200 ms, apparent TE = 105ms, vari-
able refocusing pulse flip angle to achieve T2-weighting,
acquisition matrix = 256 × 256 and spatial resolution =
1.1 mm).
Image analysis
Acquired T1-weighted images were initially transformed
into standard space by a rigid registration to the Mon-
treal Neurological Institute (MNI305) template. Ac-
quired T2 images were registered to the MNI305
template as previously described [6]. Segmentations of
the optic nerve were performed manually on about 12
consecutive coronal slices on co-registered T1- and T2-
MRIs using NiftyMIDAS (Centre for Medical Image
Computing, UCL: http://cmic.cs.ucl.ac.uk/home/soft-
ware/), starting from the most rostral slice where the
eyeball was no longer visible. The intrarater intraclass
correlation (ICC) for the optic nerve segmentation, com-
puted with a two-way random effects model, was 0.85
(95% confidence intervals: 0.50–0.96).
Statistical analysis
Statistical comparisons between animal groups were per-
formed via either a two-way analysis of variance
(ANOVA) followed by post-hoc Bonferoni post-tests for
multiple comparisons, or (un)paired t-tests for single
comparisons, using GraphPad Prism (v5 for Windows,
San Diego, CA, USA. Statistical comparisons between pa-
tient cohorts were performed via an ANOVA followed by
post-hoc Bonferoni post-tests for multiple comparisons,
using GraphPad Prism (v5 for Windows, San Diego, CA,
USA).). All individual data points are shown with mean ±
SEM for animals/participants in each group.
Results
pTau in the neurosensory retina of rTg4510 mice
Immunolabelling of total tau with the A0024 antibody in
the neurosensory retina of wildtype as well as in
rTg4510 mice showed cytosolic and neurite immunore-
activity that was strongest in the retinal ganglion cell
layer (RGCL), inner plexiform layer (IPL) and inner nu-
clear layer (INL) (Fig. 1a and d, respectively).
Co-labelling with AT8, which labels pTau, showed occa-
sional weak cell body labelling in wildtype animals (Fig.
1b) that co-localised with total tau (Fig. 1c and C’). The
red signal observed in the photoreceptor layer on Fig. 1b
was the result of the combination of photoreceptor outer
segment (POS) autofluorescence and nonspecific sec-
ondary antibody binding that did not differ from what
was observed in control sections to which no primary
antibody was added (Additional file 1: Figure S2). In
contrast, in the rTg4510 animals, numerous neuronal
somas and neurites were pTau immunopositive in the
RGCL, IPL and INL (Fig. 1e) that showed co-localisation
throughout, with more intense total tau labelling (Fig. 1f,
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white arrows) and irregular clusters extending to the PIS
were also observed (Fig. 1F’, white arrows).
Quantification of the number of cell bodies positive
for pTau as a percent of total cell nuclei numbers that
were counted as Hoechst positive labelling, showed a
significantly higher proportion of pTau immunopositive
cells in the RGCL of the central (p < 0.05) and peripheral
(p < 0.001) retinas of rTg4510 compared to wildtype
mice (Fig. 2a). Upon examination of several serial con-
focal images (z-stacks), pTau and tau inclusions in the
RGCL and INL were shown to have morphologies rem-
iniscent of flame-shaped inclusions of tangle-like tau
(Fig. 2b, white arrows). When comparing overall average
pixel intensities in pTau immunofluorescence in the cen-
tral retinas between wildtype and rTg4510 mice, we
found significantly higher labelling in the PIS (p < 0.01),
but no significant difference in RGCL, IPL and INL in
the transgenic animals (Fig. 2c). However, when the per-
ipheral retina was compared, the RGCL, IPL INL, and
the PIS, showed significantly greater pTau burden in the
rTg4510 compared to the wildtype mice (p < 0.01, p <
0.01, p < 0.05 and p < 0.001 respectively) (Fig. 2d). When
comparing pTau immunofluorescence intensities be-
tween the central and peripheral retina of the rTg4510
mice, there was a trend towards higher intensities in per-
ipheral retina of all layers but only the IPL and INL
showed statistically significant higher pTau staining in-
tensities (both p < 0.05) (Fig. 2e). Lastly, in rTg4510
retinas stained with pTau and total tau, labelling was
consistently seen in axons of the RNFL (Fig. 1f ), which
ultimately amass to form the optic nerve.
Decrease in RGC densities in rTg4510 mice
The nuclear density of the RGCL was evaluated on H&E
stained 4 μm paraffin embedded sections. RGC numbers
were significantly reduced in the central but not in the
peripheral retina of rTg4510 compared to wildtype ani-
mals (p < 0.001) (Fig. 3a). The RGC numbers were lower
in the periphery compared to the central retina in both
wildtype and rTg4510 animals (p < 0.001) (Fig. 3a).
When comparing the thickness of the IPL, no differ-
ences between the central and peripheral retina, nor be-
tween animal groups was observed (Fig. 3b). No
differences were observed in the nuclear density of the
INL between wildtype and rTg4510 mice, although there
were significantly fewer cells present in the retinal per-
iphery in all mice (Fig. 3c).
Neurodegeneration in the visual system of rTg4510 mice
To examine whether there were tau induced neurode-
generative changes in parts of the visual system, brain
T2-weighted MR images were examined (Fig. 4a). Seg-
mentation of the optic nerve demonstrated a significant
reduction in normalised (to total eye volume) optic
nerve volume in rTg4510 mice compared to wildtype an-
imals (p < 0.05) (Fig. 4b) (individual non-normalised
Fig. 1 Tau and pTau Immunoreactivity within the Neurosensory Retina of rTg4510 Mice. Representative immunofluorescence images of tau and
pTau in the neurosensory retina of wildtype (a-c) and rTg4510 (d-f) mice. Tau immunoreactivity is shown in green, pTau immunoreactivity is
shown in red, and Hoechst nuclear counterstain is shown in blue. Co-localisation of tau and pTau stains indicated with white arrow in merged
channel images (c and f), which can be observed more clearly in higher magnification images (C′ and F′). Scale bars equal to 50 μm
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Fig. 2 Quantification of Tau and pTau Immunoreactivity in the Neurosensory Retina of rTg4510 Mice. a Normalised (to total cells analysed)
quantification of the percentage of cells displaying with pTau immunopositive cytosolic staining in the Retinal Ganglion Cell Layer (RGCL) and
Inner Nuclear Layer (INL) of the central and peripheral retina. Two-way ANOVA (n = 3/4, F1,3 = 31.78, p < 0.0001). b Confocal z-stacked images
demonstrating the flame-shaped morphology of cytosolic pTau inclusions in the RGCL and INL (indicated by white arrows) and bead-like neurite
inclusions. Scale bars equal to 50 μm. Immunoreactive intensity (intensity per image pixel) of pTau in the RGCL, Inner Plexiform Layer (IPL), INL,
and inner segment of the Photoreceptor Layer (PIS) in the (c) central neurosensory retina (two-way ANOVA (n = 3/4, F1,3 = 20.08, p = 0.0002)) and
(d) peripheral retina (two-way ANOVA (n = 4, F1,3 = 63.03, p < 0.0001)). e Comparison of immunoreactive intensity between the central and
peripheral regions of the neurosensory retina in the RGCL, IPL, INL and PIS layers of the rTg4510 mice (paired t-tests). Statistical significance
indicated with asterisks: * = p < 0.05; ** = p < 0.01; *** = p < 0.001
Fig. 3 – Neurodegeneration Within Layers of the Neurosensory Retina of rTg4510 Mice. a Differences in nuclear density (nuclei per tissue area) in
the Retinal Ganglion Cell Layer (RGCL) of the central and peripheral retina of wildtype and rTg4510 mice. Two-way ANOVA (n = 6, F1,1 = 22.73, p =
0.0002). b Relative thickness (% of total neural retina) of the Inner Plexiform Layer (IPL) of the central and peripheral retina of wildtype and
rTg4510 mice, as ascertained from H&E staining. Two-way ANOVA (n = 6, F1,1 = 0.00002853, p = 0.9958). c Differences in nuclear density (nuclei per
tissue area) in the Inner Nuclear Layer (INL) of the central and peripheral retina of wildtype and rTg4510 mice. Two-way ANOVA (n = 6, F1,1 =
0.3358, p = 0.5704). Statistical significance indicated with asterisks: ** = p < 0.01; *** = p < 0.001, **** = p < 0.0001
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optic nerve and total eye volumes are shown in Add-
itional file 1: Figure S4). We also showed that optic
nerve volume was closely correlated with RGCL nuclear
density (R2 = 0.8564, p < 0.0001) (Fig. 4c). In parallel, the
optic nerve of rTg4510 mice presented with a greater
signal intensity on T2-weighted MR images (p < 0.05)
(Fig. 4d and e), suggestive of increased water content or
oedema within the optic nerve of rTg4510 animals,
which is consistent with the hypothesis of axonal
degeneration.
Parcellation of brain regions involved in visual pro-
cessing and memory from T2-weighted MR images of
the mouse brain (Fig. 5a) revealed significant atrophy
within the cortex (encompassing the visual cortex) (p <
0.001) and the hippocampus (p < 0.001) of rTg4510 mice
compared to wildtype, but not in the thalamus (encom-
passing the lateral geniculate nucleus) or superior col-
liculus (Fig. 5b). Furthermore, when the volumes of
these regions were normalised to total brain volume, sig-
nificant atrophy was still apparent in the cortex (p <
0.001) and hippocampus (p < 0.01) indicative of atrophy
over-and-above that experienced by the whole brain.
The thalamus (encompassing the lateral geniculate nu-
cleus) of the rTg4510 mice however exhibited a signifi-
cantly larger normalised volume than the wildtype mice
(p < 0.01), indicative of sparing of this brain region in the
rTg4510 mouse in relation to the extent of whole brain
atrophy (Fig. 5d). A similar, albeit not significant differ-
ence was also observed in the normalised volume of the
rTg4510 superior colliculus (Fig. 5d). These observed re-
ductions in volume within the cortex and hippocampus,
and sparing of the thalamus in this model were consist-
ent with the localised expression of mutant MAPT gene
and deposition of tau pathology in the brain (Fig. 5e and
f), indicative of tau induced neurodegeneration. More
specifically, significantly greater levels of pTau immuno-
reactivity were observed in the visual cortex (p < 0.001),
and hippocampus (p < 0.001) of rTg4510 mice compared
to wildtype animals (Fig. 5g). Subtle increases in the
level of pTau staining in the rTg4510 thalamus (encom-
passing the lateral geniculate nucleus), superior collicu-
lus, and optic tract, were also observed, however these
differences were not significant. Tau induced neurode-
generation within the brain of these animals is also
Fig. 4 Reduced Optic Nerve Volume in rTg4510 Mice Ascertained Through MRI. A Example images demonstrating the segmentation protocol
used for volumetric analysis of the optic nerve from T2-weighted MR images. (a, b, c and d) Different horizontal levels of the 3D MR images, with
the optic nerve highlighted in red. B Normalised (to total eye volume) volume of the optic nerve in wildtype and rTg4510 mice. Unpaired t-test
(n = 8, p = 0.0375). Un-normalised and total eye volumes are shown in Additional file 1: Figure S4. C Correlation between MRI derived measures of
optic nerve volume, and RGCL nuclear density derived from histology. Linear regression analysis (F1,9 = 53.66, p < 0.0001). (D) Difference in
normalised T2 signal in the optic nerve of wildtype and rTg4510 mice. Unpaired t-test (n = 8, p = 0.0393). (E) Representative T2-weighted MR
images of a cross-section of the optic nerve, with the optic nerve region pseudo colour scaled for signal intensity. Statistical significance indicated
with asterisks: * = p < 0.05, **** = p < 0.0001
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consistent with the significant amounts of both total and
phosphorylated tau species detected in CSF extracts
from rTg4510 mice, but not in wildtype animals (Add-
itional file 1: Figure S5).
Neurodegeneration in the optic nerve of frontotemporal
dementia patients
Given the specific atrophy observed in the optic nerve,
and its relationship with RGCL nuclear density in the
rTg4510 mouse model (Fig. 4c), we sought to determine
whether such changes also occur in FTD patients. The
volumes of the left and right optic nerves were manually
segmented on co-registered T1- and T2-weighted brain
MR images of MAPT mutation carrying FTD patients,
and age matched controls (Fig. 6a). Segmentations re-
vealed a significantly smaller volume of the optic nerve
in FTD patients compared to age matched controls (p <
0.01, in both left and right) (Fig. 6b). Moreover, these
significant differences persisted after optic nerve vol-
umes were normalised to total intracranial volume
(Additional file 1: Figure S6), indicative of atrophy
over-and-above that experienced by the whole brain in
these patients (p < 0.01, in both left and right) (Add-
itional file 1: Figure S6B).
Discussion
The overall finding of this study was that the visual dis-
turbances in FTD sufferers might be, at least partly, due
to tau induced degeneration in the neurosensory retina
and optic nerve. We demonstrated this through detailed
study of the eye and optic nerve of the rTg4510 mouse
model of FTD and compared observed changes to those
in the brain of the same animal. We also found that
changes observed in the mouse optic nerve were simi-
larly observed in human FTD patients, suggesting that
the optic nerve and the neurosensory retina may be
prone to tauopathic changes in FTD, and inclusion of
retinal and optic nerve examination in FTD should be
considered in the future.
Fig. 5 – Tau Deposition and Neurodegeneration of Visual Pathways in the Brains of rTg4510 Mice. a Representative MR images of the brains of
wildtype and rTg4510 mice displayed in the sagittal plane, with the visual cortex, hippocampus, thalamus and superior colliculus delineated. b
Volumes of the cortex, hippocampus (Hipp), thalamus (Thal) and superior colliculus (SuCo) as ascertained through automated parcellation of MR
images. Two-way ANOVA (n = 8, F1,3 = 307.7, p < 0.0001). c Wildtype and rTg4510 animal whole brain volumes extracted from MR images.
Unpaired t-test (n = 8, p < 0.0001). d Regional volumes displayed in (b) normalised to whole brain volume displayed in (c). Two-way ANOVA (n =
8, F1,3 = 45.30, p < 0.0001). Representative PG-5 immunoreactivity in the (e) wildtype and (f) rTg4510 brain, with visual cortex (VisCortex),
hippocampus (Hipp), thalamus (Thal), superior colliculus (SuCo) and optic tract (OpTr) delineated demonstrating forebrain localisation of pTau,
and for extraction of immunoreactivity data presented in (g) pathology in the brain. Two-way ANOVA (n = 8, F1,4 = 404.1, p < 0.0001). Statistical
significance indicated with asterisks: ** = p < 0.01; *** = p < 0.001
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In the rTg4510 mouse eye, hyperphosphorylated tau
pathology was observed mainly in the RGCL, IPL, and
INL, with additional irregular clusters within the inner
segment of the photo receptor layer (PRL), translating to
a significant reduction of nuclear density in the RGCL.
This phenomenon was observed to be more pronounced
in the peripheral as opposed to the central retina in
most layers. The significance of such anatomical organ-
isation of tauopathy in the retina is yet to be fully under-
stood, however this regional nature of retinal pathology
observed here in the rTg4510 eye mirrors the pattern of
pathology we observed recently in the retina in AD [11].
The axons of RGCs in this layer converge in the RNFL
to form the optic nerve, where we observed an elevated
T2 signal, indicative of oedema/demyelination, and a de-
crease in volume. Unsurprisingly, this optic nerve atro-
phy was associated with RGCL nuclear density loss.
Most interesting however, was that similar optic nerve
atrophy was observed in cases of human FTD, suggest-
ing that the optic nerve, and by extension, the RGCL,
are prone to tauopathic changes in FTD. The conse-
quence and pathophysiological relevance of such
changes depend upon the context of cell populations af-
fected by tauopathy. While the RGCL is composed
largely of RGCs, displaced amacrine cells (ACs) are sug-
gested to encompass up to 59% of the total cells in this
layer [38]. ACs are distinguishable from RGCs by their
smaller soma and lack of projecting axons in the RNFL,
hence these cells are unlikely to contribute directly to
the optic nerve atrophy observed here. Hence rather,
cells affected by the increase in pTau immunoreactivity
and decrease in nuclear density in the RGCL are likely
to be RGCs in origin. That being said, double staining
for pTau and markers of RGCs themselves in this retinal
layer in the rTg4510 is required in order to confirm such
a hypothesis. The INL-IPL border on the other hand is
itself dominated by ACs with around 1.7% of the cell nu-
clei here belonging to displaced RGCs [37]. Whether the
pTau immunopositive cells identified at the INL-IPL
border are actually ACs or displaced RGCs needs further
investigation. Yet it would appear, at least from data pre-
sented here from the rTg4510 mouse model of tauopa-
thy, that RGC and AC cell populations in the
neurosensory retina are the most intrinsically susceptible
to tau mediated pathology.
The morphology of RGC and AC pTau inclusions ob-
served in our study compare favourably to NFT path-
ology found in the brains of other mouse models of FTD
and human FTD itself. For example, Deters at al. [12],
describe the same AT8 positive flame-shaped and bead
like structures of pTau observed in our study (Fig. 2b) as
NFTs and somatodendendritic tau inclusions, in the
mThy1.2.hTau.P301L mouse brain. Similar morpho-
logical expression of pTau has also been described in
brains of FTD patients carrying the same P301L muta-
tion in the MAPT gene [45]. The prevailing hypothesis
from the literature is that such cytoplasmic aggregations
of pTau are pathophysiological in nature [4], and hence
we hypothesise that the pTau pathology observed in the
RGCL in the rTg4510 mouse would be detrimental to
the neuronal physiology of resident RGCs. Indeed this
idea would be consistent with previous findings from
Mazzaro et al., [27], in which reduced activity, assessed
through the use of a pattern electroretinogram (pERG)
was observed in tau laden RGCs in 5month old
mThy1.2.hTau.P301S mice. Further to this we have ob-
served a significant reduction in nuclear density in this
cell layer of the rTg4510 retina, and hence this would
Fig. 6 – Reduced Optic Nerve Volume in MAPT Mutation Carrying FTD Patients. A Example images demonstrating the segmentation protocol
used for volumetric analysis of the optic nerve from T1-weighted MR images. (a, b, c and d) Different sagittal levels of the 3D MR images, with
the optic nerve highlighted in red. B Volume of the left and right optic nerves of FTD patients and age-matched healthy controls. Two-way
ANOVA (n = 5, F1,1 = 25.57, p = 0.0001). Statistical significance indicated with asterisks: ** = p < 0.01
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suggest that the pTau labelling observed in the RGCL in
the rTg4510 mouse is capable of inducing neurodegener-
ation within this region.
From the retina, axons of RGCs project, via the RNFL
and optic nerve to the brain. Given the reduced volume
of the optic nerve in rTg4510 mice, and the association
of this measure with RGCL nuclear density, this data
would suggest tau induced neurodegeneration of RGCs
in the retina: with both somal and axonal reductions. In
the current study we have not addressed as to whether
or not the optic nerve itself is burdened by tau path-
ology, yet we show that the optic nerve, along with being
smaller in rTg4510 mice, is associated with a greater T2
signal. T2 signal is influenced by proton transfers, mo-
lecular exchange and diffusion of water, and hence an el-
evated T2 signal is suggestive of increased water content
or oedema within the optic nerve of rTg4510 animals,
which is consistent with the hypothesis of neurodegener-
ation within this region. Moreover, due to the nature of
the axonal projections from the RGCs within the eye to
the brain, the optic nerve contains a dense packed mye-
lin sheath around the axonal fibres [35]. The hydropho-
bic properties of the lipidic bilayer in myelin restricts
molecular motion of protons [5, 29] and hence hypoin-
tensity on T2-weighted MR images reflects larger myelin
content. The hyperintensity observed on T2-weighted
MR images here then would therefore also be consistent
with demyelination of the optic nerve in the rTg4510, a
phenomenon which has been previously described in
white matter regions of the rTg4510 mouse brain [33,
42]. These quantitative MR findings add weight to the
suggestion that indeed neurodegeneration of the RGC
axons in the optic nerve is taking place in the rTg4510
mouse.
MAPT P301L expression in the rTg4510 mouse is
CaMKIIa promoter driven and hence it may well be pos-
sible that pTau localisation is due to CaMKIIa expres-
sion in RGCs and AC populations. That being said, the
CaMKIIa expression profile in the mouse neurosensory
retina has not been fully elucidated in the literature. In
the rat retina, it has been shown that conventionally
placed and displaced ACs are CaMKIIa positive [34],
and in the primate retina, CaMKIIa expressing RGCs
have been shown to exist [7]. It may well be that the
specific promoter system employed in this transgenic
mouse causes expression of pTau within these cell layers.
Indeed, further assessment of tau pathology in the
rTg4510 eye should aim to determine whether or not
this is the case, through regional and cell specific profil-
ing of CaMKIIa expression in the mouse retina, to
understand the contribution of promoter-driven trans-
gene expression in the deposition of pTau pathology in
affected population in the mouse neural retina. Curious
however, that similar patterns of expression were also
noted in both the mThy1.2 and PRNP promoter driven
P301 mutant mouse lines [14, 18], suggesting the spe-
cific vulnerability of these retinal cell layers, rather than
promoter driven expression. Likewise, photoreceptors
are unlikely to express CaMKIIa, and yet tau and pTau
were both observed in this layer in the rTg4510 mouse
retina. This raises the intriguing possibility therefore that
mechanisms of tau deposition other than
promoter-driven expression, may similarly be occurring
in the rTg4510 mouse retina.
It is known that tau propagates in the brain between
functionally connected regions [1]. More specific to the
visual pathways, it was noted recently by Mazzaro et al.
[27], that after tau containing diseased brain homogen-
ate was injected into the Superior Colliculus of
mThy1.2.hTau.P301S mice, augmented cerebral, as well
as optic nerve pathological tau was evident. The retinal
expression pattern of CaMKIIa and promoter-driven tau
expression notwithstanding, these data suggest that the
retinal tau pathology observed here in the rTg4510
mouse could indeed be a consequence of tau propaga-
tion, via the optic nerve, to the retina itself, from func-
tionally connected regions of the visual pathways. As
previously mentioned, the expression of the human
MAPT gene harbouring the P301L mutation in this ani-
mal model is driven by the CaMKIIa promoter system
(Fig. 7a) and hence tau pathology is observed largely
within areas where CaMKIIa is expressed most highly,
i.e. the forebrain of mice (Fig. 5f and g), resulting in pro-
portional atrophic changes in brain volume (Fig. 5a-d),
as previously observed in this model [47]. Appropriately,
we show here that the cortex, including the visual cor-
tex, of the 7.5 month old rTg4510 mouse is heavily bur-
dened by tau pathology (Fig. 5). Yet the subcortical areas
involved in visual processing, i.e. the super colliculus
and lateral geniculate nucleus, are not overtly affected
by either tau pathology and hence nor neurodegenera-
tion, but tau levels appear to be increased compared to
controls (Fig. 5g). It is possible therefore, that the tau
pathology observed in the retina is a result of propaga-
tion from the visual cortex via the geniculate and
extra-geniculate visual pathways in the brain (Fig. 7c).
This would be consistent with findings of the propaga-
tion of tau in the brain from groups such as Ahmed at
al. [1], and Mazzaro et al. [27]. Moreover, the incidental
finding of the presence of pTau in the PRL, where pro-
moter expression is lacking, would too support, however
not prove, the idea that pTau driven pathology in the
neurosensory retina is a result of propagation.
In the current study we observed reduced optic nerve
volume in FTD patients. Similarly, in a mouse model of
the disorder, we demonstrated that reduced optic nerve
volume is accompanied by likely optic nerve demyelin-
ation (T2 hyperintensity), and associated with a
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reduction in nuclear density of the tau burdened RGCL.
Whether similar levels of neurodegeneration and reduc-
tion of RGCL nuclear density take place in the eyes with
FTD sufferers will need to be examined in clinical studies,
however our finding of reduced optic nerve volume and
changes within the neural retina in the rTg4510 mouse
model, would recommend assessment of retinal layer
thicknesses in FTD. The literature regarding retinal layer
thicknesses in FTD patients however is limited and mixed.
Specifically, using optic coherence tomography (OCT),
Ferrari et al. [13] demonstrate, consistent with the pattern
of tau pathology we observed in the mouse eye, NFL and
RGCL-IPL layer thinning in FTD compared to healthy
controls. Whereas Kim et al. [23], report that there is no
difference between inner retinal layer thicknesses of FTD
patients compared to control, but that the retinal outer
layer is thinner in FTD patients. Interestingly however, a
study by Albrecht et al. [2], reveals that patients with an-
other degeneratiuve taupathy, progressive supranuclear
palsy, exhibit reduced RGCL, IPL, and outer nuclear layer
thicknesses, but greater thickness in the outer plexiform
layer compared to control. All the aforementioned studies
however only report changes in layer thicknesses rather
than any quantitication or localisation of retinal tau path-
ology. If it is the case though, as supported by the mouse
data reported here, that in clinical FTD tau accumulates
in layers such as the RGCL leading to RGC neurodegener-
ation, findings from the glaucoma field would suggest that
altered vision is a likely consequence [3]. Together with
the atrophic changes taking place in the visual cortex, our
findings that the retina and the optic nerve are directly af-
fected by tau pathology may explain the wealth of data
linking cognitive visual changes to tauopathies [9, 10, 15,
21, 28] and may suggest that more attention should be
paid towards retinal and optic nerve changes in FTD in
the clinic. Eye imaging is significantly simpler, faster, and
better tolerated than brain imaging. Retinal imaging may
therefore serve as a surrogate marker for disease progres-
sion, benefiting both patients and the health system
enormously.
Fig. 7 – Summary of Findings of pTau Pathology in the rTg4510 Mouse Visual System. (a) Sagittal slice images from the Allen Brain Atlas (Image
credit: Allen Institute) showing expression pattern of CaMKIIa in the adult mouse brain. Schematic of the layers of the neural retina, and
immunohistochemical slice representative images of tau pathology (brown) in (b) wildtype and (c) rTg4510 mice, demonstrating the localisation
of retinal and parenchymal tau pathology in the brain, overlaid with the geniculate and extra-geniculate visual pathways for contextualisation of
the effect of tau pathology on the visual system
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In conclusion, concurrent degeneration within the
neurosensory retina and reduced volume within the
optic nerve of rTg4510 mice suggests that tau induced
degeneration may play a role in affecting signal propaga-
tion to the brain in this animal model. The volume loss
of the optic nerve in FTD patients suggests that neuro-
sensory retinal tau pathology may too exist in the eyes
of FTD patients, however this would need to be evalu-
ated and confirmed in cadaveric eyes from FTD patients,
as well as clinical OCT imaging in FTD sufferers. Cur-
rently, the consequences of such pathologies is not
known, but preventing and protecting tauopathy patients
from the cognitive visual changes routinely experienced
with disease development may represent a novel ap-
proach for improving quality of life of FTD sufferers,
and decrease the burden on carers and society by pre-
serving independent living for longer. Furthermore, it is
intriguing to speculate whether optic nerve degeneration
could be an early pathological sign of FTD, which could
be examined in further longitudinal studies, and which
would recommend inclusion of retinal and optic nerve
examination in FTD.
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